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Intensity modulated radiation therapy (IMRT) allows physicians to deliver higher confor-
mal  doses to the tumour, while avoiding adjacent structures. As a result the probability of
tumour control is higher and toxicity may be reduced. However, implementation of IMRT  is
highly complex and requires a rigorous quality assurance (QA) program both before and dur-
ing  treatment. The present article describes the process of implementing IMRT for localized
prostate cancer in a radiation therapy department. In our experience, IMRT  implementa-
tion requires careful planning due to the need to simultaneously implement specialized
software, multifaceted QA programs, and training of the multidisciplinary team. Establish-IMRT
Prostate cancer
ing  standardized protocols and ensuring close collaboration between a multidisciplinary
team is challenging but essential.
©  2014 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
of the dose delivered to the tumour and lymph nodes, while1.  IntroductionThe concept of intensity-modulated radiotherapy (IMRT) ﬁrst
appeared in 1960, and in 1966 the Sloan Kettering Memo-
rial Cancer Center was the ﬁrst to treat patients with this
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E-mail addresses: adepoite@yahoo.com.mx, adepoite@hotmail.com
http://dx.doi.org/10.1016/j.rpor.2014.06.002
1507-1367/© 2014 Greater Poland Cancer Centre. Published by Elsevier new technology.4 IMRT is a signiﬁcant advancement in the
ﬁeld of Radiation Oncology, as it allows a better conformity (M.A. Poitevin-Chacón).
avoiding irradiation of adjacent healthy structures. As a result,
there is a potential decrease in the likelihood of complications
associated with irradiation of these normal surrounding
Urban & Partner Sp. z o.o. All rights reserved.
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issues. However, high-quality IMRT  requires the support of
edical physicists and detailed knowledge of three dimen-
ional (3D) anatomy and patterns of disease spread.1
In recent years, dose escalation has been shown to improve
he probability of local tumour control in prostate cancer. As
 result, a growing number of radiotherapy departments have
ncorporated IMRT  into their routine work, and many  more
entres are in the process of doing so.2,3
Our own recent experience in implementing IMRT  has
hown us that this is a complex, time-consuming, and expen-
ive process. Some centres, particularly smaller ones, may ﬁnd
he process to be daunting. However, despite the obstacles and
ifﬁculties, it is feasible to implement IMRT  if a well-planned
pproach is taken.
The aim of the present article is to describe the process
f implementing IMRT for prostate cancer in a private radio-
herapy centre. Our experience may be useful to other centres
hat wish to implement IMRT.
.  Hospital  description
édica Sur is a large, privately owned hospital located in
exico City, Mexico. The hospital has 170 beds and treats
pproximately 1200 patients per month. The Department of
adiation Oncology is staffed by 20 physicians, 2 nurses, 4
edical physicists, 2 dosimetrists, and 8 technicians. On aver-
ge, the department treats approximately 600 patients per
ear. Available equipment includes 2 Varian linear accelera-
ors, one Siemens 16-slice PET-CT unit (shared schedules for
irtual simulation), 4 treatment planning systems (TPS) with
clipse v 7.3 software, and Varis Record and Verify system
R&V) database.
.  IMRT:  description
MRT  is a speciﬁc radiotherapy technique delivered by a lin-
ar accelerator equipped with multileaf collimator (MLC) in
hich the beams are modulated to produce highly conformal
ose distributions. A primary objective of IMRT  is to reduce the
ose to critical organs to preserve their function by restricting
he entire radiotherapy dose only to the treatment volumes.
owever, the successful delivery of IMRT  requires precise,
eproducible, and reliable patient positioning, in addition to
 rigorous quality assurance (QA) program overseen by medi-
al physicists. IMRT  is administered through treatment ﬁelds,
ach of which is individually modulated. The intensity of these
ariable doses can be managed by the segments in each treat-
ent ﬁeld.
.  IMRT  vs.  conventional  3D  planning
MRT  planning is conceptually very different from con-
entional planning. In IMRT,  the radiation oncologist must
elineate treatment volumes (tumour, lymph nodes) and crit-
cal organs (rectum, bladder, spinal cord, saliva glands, eye,
tc.), whereas in conventional 3D planning, large ﬁelds are
sed to compensate for daily variations in positioning and
he physical characteristics of the radiation beam. The doseiotherapy 2 0 ( 2 0 1 5 ) 66–71 67
distribution in conventional 3D planning is calculated in a
planning process called “forward planning” which involves
calculating the angle of incidence, the weight or contribu-
tion to the total of each beam, and the necessary beam
modiﬁer. IMRT, in contrast, requires that the radiation oncol-
ogist deﬁnes speciﬁc doses to the volumes of interest: the
gross tumour volume (GTV), clinical target volume (CTV), the
planning target volume (PTV), and to critical organs and plan-
ning risk volume (PRV) in accordance with ICRU 50/63/82
guidelines.5 The computerized IMRT planning software cre-
ates a series of modulation patterns in each incidence angle
for the beam and the prescribed doses are obtained by an iter-
ative algorithm. This process is known as “inverse planning”.
5.  Development  of  a protocol
A protocol was created to standardize IMRT  treatment pro-
cedures for localized prostate cancer. This protocol was
developed in accordance with clinical guidelines and a review
of the literature to guarantee quality assurance (QA) with
regards to technical aspects of treatment and correct physics.
The following procedures were implemented.
5.1.  Patient  preparation
The day prior to the simulation, patients are instructed to
eat a bland diet and to take 2 enemas (one at night and the
other on the day of the simulation) to avoid movement  of
the rectal wall caused by the presence of faeces or gas in the
rectum.
Thirty minutes prior to the simulation, the patient is
instructed to completely empty the bladder, drink 500 ml  of
water, and retain the urine until the end of the procedure.
5.2.  Treatment  simulation
After 30 min  have passed, the patient is positioned in the
dorsal decubitus position on the computed tomography (CT)
scanner, with the legs resting on a commercial immobiliz-
ing cushion (CIVCO; Kalona, IA, USA), hands crossed over
the chest, and the head resting on a support. The radiothe-
rapy technician creates reference points by placing radiopaque
markers on the skin of the patient at the abdominal or pelvis:
3 markers are used for axial alignment, one for sagittal align-
ment, with 2 other markers (one on each knee) to coincide
with the cushion markers. CT slices (3 mm)  are obtained in
an area that ranges from 5 cm above to 5 cm below the treat-
ment site. The reference marker sites are then immediately
tattooed and magnetic resonance images (MRI) are acquired
under the same positioning conditions, except that the metal-
lic clips are replaced by vitamin E markers. The same segment
of the abdominal-pelvic region is scanned with MRI  using the
6same CT parameters in T2-weighted sequence.
These protocols assure that each treatment is performed
under standardized conditions that can be repeated on a daily
basis.
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5.3.  Treatment  planning
The CT and MRI  images are then imported to the computer
system of the Medical Physics department where the 3D image
is reconstructed, and both images (CT and MRI) are fused to
coincide anatomically. Then, using these images, the radiation
oncologist contours the organs at risk (OAR) and treatment
volumes (GTV, CTV and PTV) using the Eclipse (v. 7.3) treat-
ment planning software (Varian Medical Systems; Palo Alto,
CA, USA).
The contoured OARs include the femoral heads, the whole
bladder, and the rectal volume—the complete rectal wall and
lumen from the anus to the rectosigmoid junction. When cre-
ating the PTV, we  initially excluded the anterior wall of the
rectum completely. However, to comply with ICRU 83,7 which
stipulates the inclusion of a 5 mm margin in the rectal wall to
account for uncertainties and internal movements, we later
changed our approach. Accordingly, the PTV in our revised
protocol now includes this 5 mm margin. In cases in which
pelvic lymph nodes need to be irradiated, the small intestine
is contoured as an OAR. The penile bulb is delineated on the
fused MRI  image.
Treatment volumes include the prostate and seminal vesi-
cles, which are contoured according to standard international
guidelines.8 The prostate PTV78, deﬁned as the treatment vol-
ume  that receives at least 95% of the prescribed dose (78 Gy),
is the CTV plus additional margins, as follows: a 7 mm mar-
gin is added laterally, anteriorly, and in the direction of the
head; a 5 mm margin is added posteriorly and towards the
feet. The daily dose prescribed to the PTV is 2 Gy for a total
dose of 78 Gy (PTV78). The PTV78 is created in consensus with
the medical physics department. In cases requiring nodal irra-
diation, delineation of this area is performed according to
the contouring atlas of the Radiotherapy Treatment Group
(RTOG).9
Once contouring has been completed, the work is checked
and, if necessary, modiﬁed. Treatment planning is completed
in one week for the prostate and in two weeks in cases in which
pelvic lymph nodes are included. Dose limitations to the OARs
were established in accordance with the published data for
acute and chronic toxicity based on studies of conformal
3D radiotherapy and calculations in dose–volume histograms
(DVH). A form with these dose restrictions was implemented
to include in each patient record (Fig. 1). The rectum, bladder,
femoral heads, small intestine, penile bulb, and dose prescrip-
tion to the PTV are included on this form.
Treatments are planned with the TPS. Although 5 ﬁelds
were used initially, we found that 7 ﬁelds improved the dosi-
metric results, with gantry angles set at 180◦, 135◦, 95–100◦,
30–35◦, 330–325◦, 260–265◦, and 225◦ (opposing parallel ﬁelds
should not be used). The sliding window IMRT technique is
used to administer 6 MV  photon radiotherapy with a Varian
Clinac (model iX). During the course of treatment, digitally
reconstructed radiographs (DRR) are created from the CT data
and transferred to the patient’s medical record for comparison
with the orthogonal portal images obtained via an electronic
portal imaging device (EPID) set in gantry positions ranging
from 0◦ to 90◦. These portal images are taken every third day
and deviations from the latero–lateral, superior–inferior and
anterior–posterior positions, based on the skin markers andFig. 1 – Dose restrictions.
pelvic bone anatomy, are measured. Any deviations greater
than 1 mm are corrected and registered on the movement  reg-
istration form (Fig. 2). If conditions in the rectum differ from
the initial conditions (due to the presence of gases or faecal
matter) treatment is suspended and the patient is instructed
to attempt to empty the rectum within 10 min, without emp-
tying the bladder. If the difference in the rectum remains, the
procedure is restarted with bladder empted. Every 10 sessions,
a CT scan is performed to assure that the image  coincides with
the initial CT scan. If large differences are observed, a new plan
is created (Fig. 3).
5.4.  Patient  positioning
Correct patient preparation with reproducible bladder ﬁlling
not only reduces internal movement  of the prostate, but can
also prevent toxicity to the seminal vesicles. Daily veriﬁca-
tion of positioning with portal imaging is useful and highly
advisable.9–12
5.5.  Assessing  toxicity
In order to properly determine the results of IMRT,  it is essen-
tial to assess acute side effects, as one of the main objectives of
IMRT is to reduce toxicity as compared to conformal 3D-RT. For
this reason, we  developed a very simple questionnaire (Fig. 4),
which is administered by the nurse during the course of treat-
ment. The nurse is responsible for registering the data from
the questionnaire and for informing the radiation oncologist
if there are any general, rectal, or urinary symptoms.13,14
5.6.  Quality  assurance  by  Medical  Physics
The following procedures are performed by the Medical
Physics Department:i. Commissioning of an IMRT planning system: this
includes adjustment of the planning system parameters,
reports of practical oncology and radiotherapy 2 0 ( 2 0 1 5 ) 66–71 69
Fig. 2 – Movement  registration.
Fig. 3 – Image overlapping.
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dosimetric tests with various phantoms, adjustment of the
radiation delivery system, and data transfer tests.
ii. Linear accelerator QA procedures: mechanical and dosi-
metric precision of the dynamic ﬁelds. QA of the MLC is
also performed. Dosimetric precision depends on the posi-
tioning accuracy of each leaf during the entire treatment.
ii. Patient-related QA procedures: veriﬁcation of the dosimet-
ric plan, and ﬁeld-by-ﬁeld dosimetric veriﬁcation.
iv. Pre-treatment QA: the speciﬁc dose for each ﬁeld in each
patient is routinely veriﬁed at the start of the morning
and afternoon.15 Veriﬁcation is carried out with a PPMA
phantom (type 2967; PTW, Freiburg, Germany).
5.7.  Dose  distribution:  calculation  and  veriﬁcation
The dose distribution is calculated on a reference plane that
is perpendicular to the central axis, with the absolute dose
calculated on a reference point. For each ﬁeld, the test plan
is transferred to the Varis Record and Verify system (R&V)
database (Varis Information Systems, Varian Oncology; Palo
Alto, CA), together with the leaf movement  plan. In the accel-
erator, the phantom is positioned according to the test plan
and a 0.3 cm3 ionization chamber (TW31013, PTW, Freiburg,
Germany) is used to measure the absolute dose. The portal
dosimetry of the EPID is used to measure the dose distribution
on the reference plane.15–17
Administration of the QA ﬁelds is performed with the Varis
R&V System. This is done not only to corroborate the dosimet-
ric precision of the IMRT ﬁelds, but also to assure the correct
transfer of data from the TPS to the veriﬁcation system (Fig.
5).
Next, the dose at various points is measured to conﬁrm
that the irradiated ﬁelds are correct. To measure the doses,
the ionization chamber is positioned in the centre of the axis;
however, if a wide gradient is detected in the central axis, a
different measuring point is selected.
5.8.  Gamma  index
The results of the 2D distributions are analysed with an eval-
uation method called gamma  index. This method allows us
to compare two dose distributions even in regions with steep
gradients in which other methods (such as superimposing iso-
dose distributions or by dose differentials) are not sufﬁciently
precise. The gamma index has to be adjusted by the accepta-
tion criteria provided by the user for the difference between
the maximum dose and the distance to agreement (DTA). Only
areas with gamma = 1 meet the acceptation criteria. Accepta-
tion criteria were deﬁned as a maximum deviation from the
absolute dose of 2% and a DTA of 2 mm.
Superimposition of absolute and calculated isodose meas-
ures is represented together with corresponding gamma  index
distribution. The corresponding gamma index values are
generally less than 1, and thus meet the criteria described
above. For very small areas, the dose difference is 3%, these
deviations can be explained by underdosing due to the tongue-
and-groove effect between adjacent leafs, which are not
correctly modelled by the Eclipse. For this reason, it seems that
a treatment plan is acceptable despite the small areas where
the dose differential exceeds 2%.diotherapy 2 0 ( 2 0 1 5 ) 66–71
6.  Patients
To date, we have used IMRT  to treat 100 prostate cancer
patients. In all cases, we used the QA procedures described
above. The movement  registration form, which was devel-
oped to record the movement  (in mm)  of each patient, was
not available initially. A prescription form was implemented
in planning to facilitate and record the dose restrictions to
the critical organs and the dose to the PTV. Although 5 beam
angles were used initially, we  found that 7 beam angles
resulted in a better dose distribution. Originally, the anterior
wall of the rectum was excluded from the PTV; however, fol-
lowing the ICRU 83 recommendations, a 5 mm  margin was
later included. The DVHs were checked for each patient to con-
ﬁrm the accuracy of the prescription dose and the dose to the
OARs (Fig. 6).
The nurses were responsible for administering the treat-
ment symptom tolerance questionnaire; this form was
modiﬁed to meet the requisites of the hospital’s Quality Con-
trol Department.
The main elements of a QA program for IMRT  treatment
of prostate cancer patients are strict patient selection, careful
treatment planning and execution, precise positioning, and
frequent veriﬁcations via regular electronic portal images.18–21
7.  Conclusions
Implementation of IMRT into routine clinical practice is fea-
sible but requires careful planning, particularly to achieve
quality assurance. The need to simultaneously implement
specialized software, multifaceted QA programs for all the
new software, and training and education for the multidisci-
plinary team make IMRT  implementation even more  complex.
An intensive QA program assures the administration of uni-
form treatments for better tumour control and prevention of
acute and chronic toxicity caused by radiation.
In our experience, we found that the key to success-
ful implementation of IMRT is strong leadership, extensive
training, creation of a standardized protocol, and a collab-
orative approach. In addition, it is essential that the centre
have sufﬁcient resources (staff, technology, funds) to assure
success.
IMRT was found to be feasible and immediately accepted
by all staff members, including medical physicists, radiation
oncologists, dosimetrists, and radiotherapy technicians.
Conﬂict  of  interest
None declared.Financial  disclosure
None declared.
d rad
A
S
f
2
r
1
1
1
1
1
1
1
1
1
1
2reports of practical oncology an
ppendix  A.  Supplementary  data
upplementary data associated with this article can be
ound, in the online version, at http://dx.doi.org/10.1016/j.rpor.
014.06.002.
 e  f  e  r  e  n  c  e  s
1. Hong TS, Ritter MA, Tome WA, Harari PM.
Intensity-modulated radiation therapy: emerging cancer
treatment technology. Br J Cancer 2005;92:1819–24.
2. Cahlon O, Hunt M, Zelefsky MJ. Intensity-modulated
radiation therapy supportive data for prostate cancer. Semin
Radiat Oncol 2008;18:48–57.
3. Amin N, Konski AA. Intensity-modulated radiation therapy
for prostate cancer is cost effective and improves therapeutic
ratio. Expert Rev Pharmacoecon Outcomes Res 2012;12(4):447–50.
4. Ling CC, Burman C, Chui CS, et al. Conformal radiation
treatment of prostate cancer using inversely planned
intensity modulated photon beams produced with dynamic
multileaf collimation. Int J Radiat Oncol Biol Phys
1996;35:721–30.
5. Prescribing, recording, and reporting photon beam therapy
(supplement to ICRU report 50). ICRU report 62.
6. Hanvey S, Sadozye AH, McJury M, Glegg M, Foster J. The
inﬂuence of MRI scan position on image  registration
accuracy, target delineation and calculated dose in prostatic
radiotherapy. Br J Radiol 2012;85(1020):e1256–62.
7. Prescribing, recording, and reporting photon-beam
intensity-modulated radiation therapy (IMRT) contents. J
ICRU 2010;10(April (1)).
8. McLaughlin P, Evans C, Feng M, Narayana V. Radiographic and
anatomic basis for prostate contouring errors and methods
to  improve prostate countering accuracy. Int J Radiat Oncol Biol
Phys 2010;76:369–78.9. Matsumoto K, Okumura M, Asai Y, Shimomura K, Tamura M,
Nishimura Y. Dosimetric properties and clinical application
of an a-Si EPID for dynamic IMRT quality assurance. Radiol
Phys Technol 2013;6(1):210–8.
2iotherapy 2 0 ( 2 0 1 5 ) 66–71 71
0. Boehmera D, Bohsungb J, Eichwurzelb I, Moysb A, Budacha V.
Clinical and physical quality assurance for intensity
modulated radiotherapy of prostate cancer. Radiother Oncol
2004;71:319–25.
1. Bekelman JE, Hahn SM. The body of evidence for advanced
technology in radiation oncology. J Natl Cancer Inst
2013;105(1):6–7.
2. Mendenhall NP, Schild S, Slater J. Radiation therapy
modalities for prostate cancer. JAMA 2012;308(5):450–1,
author reply 451-2.
3. Gay HA, Barthold HJ, O’Meara E, et al. Pelvic normal tissue
contouring guidelines for radiation therapy: a Radiation
Therapy Oncology Group consensus panel atlas. Int J Radiat
Oncol Biol Phys 2012;83(3):e353–62.
4. Koh WY, Ren W, Mukherjee RK, Chung HT. Internal audit of a
comprehensive IMRT program for prostate cancer: a model
for centers in developing countries? Int J Radiat Oncol Biol Phys
2009;74(5):1447–54.
5. MacKay RI, Staffurth J, Poynter A, Routsis D, Radiotherapy
Development Board. UK guidelines for the safe delivery of
intensity-modulated radiotherapy. Clin Oncol (R Coll Radiol)
2010;22(8):629–35.
6. Stasi M, Bresciani S, Miranti A, Maggio A, Sapino V, Gabriele P.
Pretreatment patient-speciﬁc IMRT quality assurance: a
correlation study between gamma index and patient clinical
dose volume histogram. Med Phys 2012;39(12):7626–34.
7. Corral Garcia A, Gómez Fervienza J, Marquez Parro R, et al.
Dosimetric effect of daily setup correction in prostate IMRT.
Rep Pract Oncol Radiother 2013;18:S379.
8. Wolff JM, Mason M. Drivers for change in the management of
prostate cancer – guidelines and new treatment techniques.
BJU Int 2012;109(Suppl. 6):33–41.
9. Bak K, Dobrow M, Hodgson D, Whitton A. Factors affecting
the implementation of complex and evolving technologies:
multiple case study of intensity-modulated radiation therapy
(IMRT) in Ontario, Canada. BMC Health Serv Res 2011;11:178.
0. Martin JM, Frantzis J, Eade T, Chung P. Clinician’s guide to
prostate IMRT plan assessment and optimization. J Med
Imaging Radiat Oncol 2010;54:569–75.1. Adamczyk M, Piotrowski T, Adamiak E. Evaluation of
combining bony anatomy and soft tissue position correction
strategies for IMRT prostate cancer patients. Rep Pract Oncol
Radiother 2012;17(2):104–9.
